Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Biotechnology

Healthcare
$41.37 +3.19%

+$1.11 today

Market cap
$4.45B
Beta
0.30
P/E (TTM)
-21.9
EPS (TTM)
-$1.64
52W Low $12.15High $40.77

Volume 0.87M

Average 1.32M

EWTX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Edgewise Therapeutics, Inc.NASDAQ: EWTX

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables outflow grows to $0

Q3 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How EWTX compares with its peers on the latest reported figures

  • EWTX's LTM Sep 2026 accounts receivables of $0 is the 6th largest of the 10 companies compared; the peer median is $0.
EWTX Competitors Peer median
Accounts Receivables for EWTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$264.55M +194.3%—12.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$44.38M -720.6%-40.6%4.4%
STOKStoke Therapeutics, Inc.LTM Mar 2026$4.8M +1478.7%—15.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$1.26M -98.3%—21.9%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$59.83K -100.0%——
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$0 ———
DYNDyne Therapeutics, Inc.LTM Jun 2026$0 ———
SLDBSolid Biosciences Inc.LTM Mar 2026$0 ———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 ———
PEPGPepGen Inc.LTM Mar 2026$0 ———
Peer median (excluding EWTX) $0-98.3%-40.6%13.5%

Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.81M)(67.64M)(100.16M)(133.81M)(167.8M)
Depreciation & Amortization272K538K1.73M2.29M2.27M
Deferred Income Tax(2.29M)0000
Stock-Based Compensation4.4M10.92M17.56M24.71M34.75M
Change in Working Capital4.63M4.09M(1.56M)10.33M(5.37M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.65M47K(92K)1.74M272K
Other Working Capital1.98M4.04M(1.47M)8.59M(5.65M)
Other Non-Cash Items2.29M(543K)(9.52M)(12.55M)(7.67M)
Operating Cash Flow(33.51M)(52.64M)(91.95M)(109.03M)(143.82M)
Capital Expenditures(668K)(5.55M)(5.75M)(1.31M)(256K)
Acquisitions (Net)241.56K65.03K000
Purchases of Investments(288.2M)(292.39M)(255.87M)(477.06M)(527.23M)
Sales of Investments46.64M227.36M364.5M293.71M494.69M
Other Investing Activities(241.56K)(65.03K)000
Investing Cash Flow(242.23M)(70.58M)102.89M(184.66M)(32.79M)
Debt Repayment00000
Common Stock Issued186.15M129.17M52.62M239.15M196.09M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities236K474K548K10.11M0
Financing Cash Flow186.38M129.64M53.17M249.25M196.09M
Effect of Forex Changes00000
Net Change in Cash(89.35M)6.43M64.1M(44.43M)19.48M
Free Cash Flow(34.18M)(58.18M)(97.69M)(110.34M)(143.82M)

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Intrinsic Alpha fair value

Locked

Current Price

$41.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.